Expression of surface antigens on CD34+/CD38− and CD34+/CD38+ cells in patients with CML and in normal/reactive BM
| . | . | Expression on CP CML cells . | Expression on AP CML cells . | Expression on normal BM cells . | |||
|---|---|---|---|---|---|---|---|
| CD . | Antigen . | CD34+/CD38− . | CD34+/CD38+ . | CD34+/CD38− . | CD34+/CD38+ . | CD34+/CD38− . | CD34+/CD38+ . |
| CD9 | Tetraspanin 29 | + | + | n.t. | n.t. | +/− | +/− |
| CD25 | IL-2RA | ++ | +/– | ++ | + | − | +/− |
| CD26 | DPPIV | ++ | +/− | ++ | +/− | − | − |
| CD33 | Siglec-3 | ++ | ++ | ++ | ++ | + | ++ |
| CD36 | TSPR | +/− | + | n.t. | n.t. | − | +/− |
| CD41 | ITGA2B | + | + | +/− | +/− | + | + |
| CD42b | GP1BA | − | − | − | − | − | − |
| CD44 | Pgp1 | ++ | ++ | ++ | ++ | ++ | ++ |
| CD46 | MCP | ++ | ++ | ++ | ++ | ++ | ++ |
| CD49f | ITGA6B | + | + | + | +/− | + | + |
| CD52 | CAMPATH | + | +/− | n.t. | n.t. | + | + |
| CD62 | SELP | − | − | − | − | − | − |
| CD90 | Thy-1 | + | +/− | n.t. | n.t. | + | +/− |
| CD96 | Tactile | − | − | − | − | − | − |
| CD105 | Endoglin | ++ | ++ | ++ | ++ | + | + |
| CD114 | G-CSFR | + | +/− | + | +/− | + | + |
| CD117 | SCFR/KIT | ++ | ++ | ++ | ++ | ++ | ++ |
| CD123 | IL-3RA | + | + | + | + | +/− | + |
| CD130 | IL6ST | − | − | − | − | +/− | +/− |
| CD133 | Prominin 1 | ++ | +/− | ++ | +/− | ++ | ++ |
| CD135 | FLT3 | + | +/− | + | +/− | + | + |
| CD151 | RAPH | + | + | + | + | + | + |
| CD164 | Sialomucin | + | + | + | + | ++ | ++ |
| CD184 | CXCR4 | + | + | + | + | + | + |
| CD200 | OX2 | ++ | + | + | + | ++ | ++ |
| CD203c | ENPP3 | − | − | − | − | − | − |
| CD243 | MDR1 | − | − | − | − | − | − |
| CD271 | NGF-R | − | − | n.t. | n.t. | − | − |
| n.c. | CLL1 | +/− | +/− | n.t. | n.t. | − | +/− |
| n.c. | IL-1RAP | + | + | n.t. | n.t. | − | +/− |
| n.c. | NPDC1 | + | + | n.t. | n.t. | + | + |
| n.c. | ROBO4 | + | +/− | n.t. | n.t. | + | +/− |
| . | . | Expression on CP CML cells . | Expression on AP CML cells . | Expression on normal BM cells . | |||
|---|---|---|---|---|---|---|---|
| CD . | Antigen . | CD34+/CD38− . | CD34+/CD38+ . | CD34+/CD38− . | CD34+/CD38+ . | CD34+/CD38− . | CD34+/CD38+ . |
| CD9 | Tetraspanin 29 | + | + | n.t. | n.t. | +/− | +/− |
| CD25 | IL-2RA | ++ | +/– | ++ | + | − | +/− |
| CD26 | DPPIV | ++ | +/− | ++ | +/− | − | − |
| CD33 | Siglec-3 | ++ | ++ | ++ | ++ | + | ++ |
| CD36 | TSPR | +/− | + | n.t. | n.t. | − | +/− |
| CD41 | ITGA2B | + | + | +/− | +/− | + | + |
| CD42b | GP1BA | − | − | − | − | − | − |
| CD44 | Pgp1 | ++ | ++ | ++ | ++ | ++ | ++ |
| CD46 | MCP | ++ | ++ | ++ | ++ | ++ | ++ |
| CD49f | ITGA6B | + | + | + | +/− | + | + |
| CD52 | CAMPATH | + | +/− | n.t. | n.t. | + | + |
| CD62 | SELP | − | − | − | − | − | − |
| CD90 | Thy-1 | + | +/− | n.t. | n.t. | + | +/− |
| CD96 | Tactile | − | − | − | − | − | − |
| CD105 | Endoglin | ++ | ++ | ++ | ++ | + | + |
| CD114 | G-CSFR | + | +/− | + | +/− | + | + |
| CD117 | SCFR/KIT | ++ | ++ | ++ | ++ | ++ | ++ |
| CD123 | IL-3RA | + | + | + | + | +/− | + |
| CD130 | IL6ST | − | − | − | − | +/− | +/− |
| CD133 | Prominin 1 | ++ | +/− | ++ | +/− | ++ | ++ |
| CD135 | FLT3 | + | +/− | + | +/− | + | + |
| CD151 | RAPH | + | + | + | + | + | + |
| CD164 | Sialomucin | + | + | + | + | ++ | ++ |
| CD184 | CXCR4 | + | + | + | + | + | + |
| CD200 | OX2 | ++ | + | + | + | ++ | ++ |
| CD203c | ENPP3 | − | − | − | − | − | − |
| CD243 | MDR1 | − | − | − | − | − | − |
| CD271 | NGF-R | − | − | n.t. | n.t. | − | − |
| n.c. | CLL1 | +/− | +/− | n.t. | n.t. | − | +/− |
| n.c. | IL-1RAP | + | + | n.t. | n.t. | − | +/− |
| n.c. | NPDC1 | + | + | n.t. | n.t. | + | + |
| n.c. | ROBO4 | + | +/− | n.t. | n.t. | + | +/− |
CP, chronic phase; AP, accelerated phase; CLL1, C type lectin-like molecule 1; CML, chronic myeloid leukemia; DPPIV, dipeptidylpeptidase IV; G-CSF, granulocyte colony-stimulating factor; IL-2, interleukin-2; n.c., not yet clustered; NGF, nerve growth factor; n.t., not tested; SCF, SC factor; TSPR, thrombospondin receptor; ++, strongly expressed in a majority of cases; +, clear expression in majority of cases; +/−, expression in minority of cases or weak expression in majority of cases; −, no expression in a vast majority of cases.